|
ニワ ユキコ
NIWA Yukiko
丹羽 由紀子 所属 医学部 医学科（附属八千代医療センター） 職種 講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study. |
| 掲載誌名 | 正式名：Nagoya journal of medical science 略 称：Nagoya J Med Sci ISSNコード：21863326/00277622 |
| 掲載区分 | 国内 |
| 巻・号・頁 | 81(2),pp.233-239 |
| 著者・共著者 | Takano Nao, Yamada Suguru, Hirakawa Akihiro, Yokoyama Yukihiro, Kawashima Hiroki, Maeda Osamu, Okada Tohru, Ohno Eizaburo, Yamaguchi Junpei, Ishikawa Takuya, Sonohara Fuminori, Suenaga Masaya, Takami Hideki, Hayashi Masamichi, Niwa Yukiko, Hirooka Yoshiki, Ito Yoshiyuki, Naganawa Shinji, Ando Yuichi, Nagino Masato, Goto Hidemi, Fujii Tsutomu, Kodera Yasuhiro |
| 発行年月 | 2019/05 |
| 概要 | The efficacy of nab-paclitaxel combined with gemcitabine (GnP) and of chemoradiotherapy (CRT) for unresectable locally advanced pancreatic ductal adenocarcinoma (UR-LA PDAC) is still unclear. We previously conducted a phase I study of CRT using GnP and determined the recommended dose and have now designed a phase II trial to evaluate the efficacy of CRT incorporating GnP for UR-LA PDAC. Eligibility criteria are chemotherapy-naïve patients with UR-LA PDAC as defined by the NCCN guidelines version 2. 2016. Study patients will receive 100 mg/m2 nab-paclitaxel and 800 mg/m2 gemcitabine on Days 1, 8, and 15 per 4-week cycle with concurrent radiation therapy (total dose of 50.4 Gy in 28 fractions of 1.8 Gy per day, 5 days per week). Treatment will be continued until disease progression or surgery, which is to be performed only for patients in whom the disease is well-controlled at 8 months from beginning the protocol treatment. Primary endpoint is 2-year overall survival rate and co-primary endpoint is resection rate. Secondary endpoints are overall survival, progression free survival, time to treatment failure, response rate, disease control rate, early tumor shrinkage, depth of response, reduction of SUV-max on PET-CT, serum tumor markers, relative dose intensity, safety, and Quality of life. This study will show the efficacy and safety of chemoradiotherapy combined with GnP. |
| DOI | 10.18999/nagjms.81.2.233 |
| PMID | 31239592 |